(TARS) Tarsus Pharmaceuticals - Ratings and Ratios
Demodex, Blepharitis, Mites, Eye Drops
TARS EPS (Earnings per Share)
TARS Revenue
Description: TARS Tarsus Pharmaceuticals August 10, 2025
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) is a US-based pharmaceutical company. The companys stock performance and financials indicate a complex situation that requires a nuanced analysis. With a market capitalization of approximately $2.01 billion USD, TARS is a mid-cap stock in the pharmaceutical industry.
The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that the company is currently unprofitable, which is corroborated by the negative Return on Equity (RoE) of -32.36%. This indicates significant losses relative to shareholder equity, a common trait among growth-stage biotech firms investing heavily in R&D.
Key economic drivers for TARS include the success of its pipeline drugs, particularly those in late-stage development. The pharmaceutical industry is highly competitive, with success often dependent on FDA approvals, market demand, and the ability to maintain patent protection. The companys ability to manage R&D expenses while advancing its pipeline will be crucial for future profitability.
To evaluate TARS potential, critical KPIs to monitor include: (1) Cash Burn Rate, to assess how quickly the company is using its cash reserves; (2) Pipeline Progress, specifically the advancement and potential approval of key drugs; (3) R&D Expenses as a percentage of revenue or cash reserves, to gauge the investment in future growth; and (4) Regulatory milestones, such as FDA meeting outcomes or approvals.
Investors should also consider the competitive landscape and market trends in the pharmaceutical sector, particularly in the therapeutic areas where TARS is focused. The companys valuation, despite current losses, may be justified by the potential for future earnings if its pipeline drugs are successful.
TARS Stock Overview
| Market Cap in USD | 3,079m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-10-16 |
TARS Stock Ratings
| Growth Rating | 58.2% |
| Fundamental | 37.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 27.4% |
| Analyst Rating | 4.63 of 5 |
TARS Dividends
Currently no dividends paidTARS Growth Ratios
| Growth Correlation 3m | 78.3% |
| Growth Correlation 12m | 19.3% |
| Growth Correlation 5y | 42.6% |
| CAGR 5y | 57.07% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.21 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.40 |
| Sharpe Ratio 12m | 0.03 |
| Alpha | 40.92 |
| Beta | 0.811 |
| Volatility | 50.98% |
| Current Volume | 524k |
| Average Volume 20d | 543.4k |
| Stop Loss | 65.1 (-5.4%) |
| Signal | 0.36 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-92.0m TTM) > 0 and > 6% of Revenue (6% = 17.7m TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 15.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 130.0% (prev 373.0%; Δ -243.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -80.9m > Net Income -92.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (42.4m) change vs 12m ago 12.00% (target <= -2.0% for YES) |
| Gross Margin 93.36% (prev 92.50%; Δ 0.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.79% (prev 22.12%; Δ 45.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.47 (EBITDA TTM -85.0m / Interest Expense TTM 9.21m) >= 6 (WARN >= 3) |
Altman Z'' -1.55
| (A) 0.78 = (Total Current Assets 474.4m - Total Current Liabilities 90.3m) / Total Assets 495.0m |
| (B) -0.82 = Retained Earnings (Balance) -405.7m / Total Assets 495.0m |
| (C) -0.20 = EBIT TTM -87.2m / Avg Total Assets 435.9m |
| (D) -2.50 = Book Value of Equity -405.6m / Total Liabilities 162.4m |
| Total Rating: -1.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.45
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -3.17% = -1.59 |
| 3. FCF Margin -29.72% = -7.50 |
| 4. Debt/Equity 0.22 = 2.48 |
| 5. Debt/Ebitda 0.28 = 2.44 |
| 6. ROIC - WACC (= -33.34)% = -12.50 |
| 7. RoE -32.36% = -2.50 |
| 8. Rev. Trend 87.62% = 6.57 |
| 9. EPS Trend 60.98% = 3.05 |
What is the price of TARS shares?
Over the past week, the price has changed by +4.16%, over one month by +15.78%, over three months by +77.25% and over the past year by +54.66%.
Is Tarsus Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TARS is around 74.74 USD . This means that TARS is currently overvalued and has a potential downside of 8.62%.
Is TARS a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TARS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78.4 | 13.9% |
| Analysts Target Price | 78.4 | 13.9% |
| ValueRay Target Price | 83.6 | 21.5% |
TARS Fundamental Data Overview October 20, 2025
P/S = 10.4178
P/B = 7.4589
Beta = 0.811
Revenue TTM = 295.5m USD
EBIT TTM = -87.2m USD
EBITDA TTM = -85.0m USD
Long Term Debt = 72.1m USD (from longTermDebt, last quarter)
Short Term Debt = 317.0k USD (from shortTermDebt, last quarter)
Debt = 72.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -24.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.77b USD (3.08b + Debt 72.4m - CCE 381.1m)
Interest Coverage Ratio = -9.47 (Ebit TTM -87.2m / Interest Expense TTM 9.21m)
FCF Yield = -3.17% (FCF TTM -87.8m / Enterprise Value 2.77b)
FCF Margin = -29.72% (FCF TTM -87.8m / Revenue TTM 295.5m)
Net Margin = -31.13% (Net Income TTM -92.0m / Revenue TTM 295.5m)
Gross Margin = 93.36% ((Revenue TTM 295.5m - Cost of Revenue TTM 19.6m) / Revenue TTM)
Gross Margin QoQ = 93.92% (prev 93.35%)
Tobins Q-Ratio = 5.60 (Enterprise Value 2.77b / Total Assets 495.0m)
Interest Expense / Debt = 3.09% (Interest Expense 2.24m / Debt 72.4m)
Taxrate = -0.0% (0.0 / -115.6m)
NOPAT = -87.2m (EBIT -87.2m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 5.26 (Total Current Assets 474.4m / Total Current Liabilities 90.3m)
Debt / Equity = 0.22 (Debt 72.4m / totalStockholderEquity, last quarter 332.6m)
Debt / EBITDA = 0.28 (negative EBITDA) (Net Debt -24.2m / EBITDA -85.0m)
Debt / FCF = 0.28 (negative FCF - burning cash) (Net Debt -24.2m / FCF TTM -87.8m)
Total Stockholder Equity = 284.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.58% (Net Income -92.0m / Total Assets 495.0m)
RoE = -32.36% (Net Income TTM -92.0m / Total Stockholder Equity 284.3m)
RoCE = -24.46% (EBIT -87.2m / Capital Employed (Equity 284.3m + L.T.Debt 72.1m))
RoIC = -24.48% (negative operating profit) (NOPAT -87.2m / Invested Capital 356.2m)
WACC = 8.86% (E(3.08b)/V(3.15b) * Re(9.0%) + D(72.4m)/V(3.15b) * Rd(3.09%) * (1-Tc(-0.0)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.16%
Fair Price DCF = unknown (Cash Flow -87.8m)
EPS Correlation: 60.98 | EPS CAGR: 17.19% | SUE: 2.65 | # QB: 1
Revenue Correlation: 87.62 | Revenue CAGR: 311.3% | SUE: 1.59 | # QB: 3
Additional Sources for TARS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle